Pancreatic islet transplantation into the bone marrow of the rat

American Journal of Surgery
Anastasio Salazar-BañuelosLuis Benítez-Bribiesca

Abstract

The liver is the current site for pancreatic islet transplantation, but presents important technical complications and limitations. We asked whether pancreatic islets could be engrafted in the bone marrow, an easily accessible and widely distributed transplant site that may lack the limitations seen in the liver. We implanted pancreatic islet isografts (Lewis islets to Lewis rats), allografts (Wistar Furth islets to Sprague Dawley rats), and xenografts (Tilapia islets to Sprague Dawley rats) into the bone marrow of nondiabetic recipients and assessed survival by histology and immunocytochemistry. No immunosuppression was used. Isografts and allografts showed positive staining for insulin and glucagon and no evidence of allograft rejection up to 21 days posttransplant. Xenografts were acutely rejected. The bone marrow may be an attractive alternative site for pancreatic islet transplantation. The acceptance of allografts and isografts but rejection of xenografts suggests a selective phenomenon for the inflammatory process.

References

Apr 1, 1994·The Journal of Surgical Research·P C WattE P Passaro
Apr 9, 1998·Transplantation Proceedings·A M ShapiroN Kneteman
Jan 31, 2002·Archives of Surgery·Charles P MorrisonGuy J Maddern
Oct 24, 2002·Transplantation·John J CaseyA M Shapiro
Feb 5, 2003·Ophthalmic Research·M InoueD L Hatchell
Apr 6, 2005·Xenotransplantation·Ayman Al-JazaeriJames R Wright
May 10, 2005·Biomaterials·Marina FigliuzziAndrea Remuzzi
Nov 24, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·P VilligerA M James Shapiro
Dec 17, 2005·Cell Transplantation·Craig R HalberstadtPaul F Gores
Mar 29, 2006·Diabetes Care·R Paul RobertsonUNKNOWN American Diabetes Association
Sep 29, 2006·The New England Journal of Medicine·A M James ShapiroJonathan R T Lakey

❮ Previous
Next ❯

Citations

Jul 27, 2011·Current Diabetes Reports·Elisa Cantarelli, Lorenzo Piemonti
Sep 24, 2009·Blood·Elisa CantarelliLorenzo Piemonti
May 1, 2010·Blood·Anastasio Salazar-BañuelosJames R Wright
Oct 10, 2013·Clinical & Developmental Immunology·Andrew R PepperA M James Shapiro
Jan 13, 2009·Xenotransplantation·Mårten K J Schneider, Jörg D Seebach
Nov 11, 2008·The British Journal of Surgery·S MeraniA M J Shapiro
Sep 4, 2013·Diabetes/metabolism Research and Reviews·Naoaki SakataMichiaki Unno
Jun 29, 2011·Arquivos De Gastroenterologia·Yngrid Ellyn Dias Maciel de SouzaLuiz Augusto Carneiro D'Albuquerque
Aug 26, 2018·Biotechnology and Bioengineering·Marcos Perez-BasterrecheaAlvaro J Obaya
Sep 26, 2009·Current Opinion in Organ Transplantation·Olle Korsgren, Bo Nilsson
Oct 14, 2014·World Journal of Gastroenterology : WJG·Leandro Ryuchi IuamotoLuiz Augusto Carneiro D'Albuquerque

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis